• 1. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 2. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid (CAS No. 1994-11-2): A Comprehensive Overview

7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 1994-11-2, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the cinnoline family, which is known for its diverse biological activities and potential therapeutic applications. The presence of both fluoro and hydroxyl substituents in its molecular structure imparts unique chemical and pharmacological properties, making it a subject of extensive research and development.

The structural framework of 7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid consists of a fused bicyclic system comprising a benzene ring and a pyridine ring. The fluoro group at the 7-position and the hydroxyl group at the 4-position are key functional elements that influence its reactivity, solubility, and interaction with biological targets. These substituents contribute to its potential as a scaffold for drug discovery, particularly in the development of novel therapeutic agents targeting various diseases.

In recent years, there has been a growing interest in exploring the pharmacological properties of cinnoline derivatives. 7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid has been investigated for its potential role in inhibiting specific enzymes and receptors involved in inflammatory responses, cancer progression, and microbial infections. The fluoro substituent, in particular, has been shown to enhance metabolic stability and binding affinity, which are crucial factors in drug design.

One of the most compelling aspects of 7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid is its versatility as a building block for more complex molecules. Researchers have utilized this compound to synthesize derivatives with enhanced bioavailability and targeted action. For instance, modifications at the 3-carboxylic acid position have led to the development of novel compounds with improved pharmacokinetic profiles. These derivatives are being evaluated in preclinical studies for their efficacy against various pathological conditions.

The synthesis of 7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, including palladium-catalyzed cross-coupling reactions and enzymatic resolutions, have been employed to optimize the synthesis process. These techniques not only improve efficiency but also minimize environmental impact, aligning with the principles of green chemistry.

The biological activity of 7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid has been studied extensively in vitro and in vivo. Preliminary findings suggest that this compound exhibits inhibitory effects on several key enzymes implicated in disease pathways. For example, it has shown promise in reducing inflammation by modulating cytokine production and inhibiting pro-inflammatory enzymes such as COX-2 and LOX. Additionally, its ability to interact with bacterial enzymes has led to investigations into its potential as an antimicrobial agent.

In the realm of oncology, 7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid has been explored as a candidate for developing chemotherapeutic agents. Its structural features allow it to interfere with critical cellular processes involved in cancer cell proliferation and survival. Preclinical studies have demonstrated its ability to induce apoptosis in certain cancer cell lines while sparing healthy cells. This selective toxicity makes it an attractive candidate for further development into a novel anticancer drug.

The role of computational chemistry in understanding the behavior of 7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid cannot be overstated. Molecular modeling techniques have been employed to predict its binding interactions with biological targets at the atomic level. These simulations provide valuable insights into how the compound exerts its pharmacological effects and guide the design of more potent derivatives.

The future prospects for 7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid are promising, with ongoing research aimed at elucidating its mechanism of action and optimizing its pharmacological properties. Collaborative efforts between academic institutions and pharmaceutical companies are likely to accelerate the translation of laboratory findings into clinical applications. As our understanding of disease mechanisms continues to evolve, compounds like this will play an increasingly important role in developing innovative treatments.

In conclusion, 7-Fluoro-4-hydroxy-cinnoline-3-carboxylic acid (CAS No. 1994-11-2) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and diverse biological activities. Its potential applications span multiple therapeutic areas, making it a valuable asset in the quest for novel therapeutic agents. With continued research and development, this compound is poised to make substantial contributions to human health and well-being.

• 887569-47-3(6-FLUORO-4-HYDROXY-3-(1H)INDAZOLE CARBOXYLIC ACID)
• 612511-48-5(3-Cinnolinecarboxylic acid, 6-fluoro-4-hydroxy-, ethyl ester)
• 612511-49-6(3-CINNOLINECARBOXYLIC ACID, 8-FLUORO-4-HYDROXY-, ETHYL ESTER)
• 90771-53-2(3-Cinnolinecarboxylic acid, 4-hydroxy-6-methoxy-)
• 114610-24-1(3-Cinnolinecarboxylic acid, 6,7-difluoro-4-hydroxy-, ethyl ester)
• 887569-55-3(6-Fluoro-4-methoxy-3-(1H)indazole carboxylic Acid)
• 36991-64-7(6-Isobutyl-4-oxo-1,4-dihydrocinnoline-3-carboxylic acid)
• 887569-23-5(4-fluoro-6-methoxy-1H-indazole-3-carboxylic acid)
• 887569-35-9(4-FLUORO-6-HYDROXY-3-(1H)INDAZOLE CARBOXYLIC ACID)
• 1994-12-3(8-fluoro-4-hydroxycinnoline-3-carboxylic acid)